We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 1,887

Stakeholders Voice Opinions About Modernizing “Healthy” at FDA Meeting
  • Shook Hardy & Bacon LLP
  • USA
  • March 17 2017

Concerns about how or whether the term "healthy" should be used in food labeling and packaging prompted the U.S. Food and Drug Administration (FDA


Study Claims Honeybee Gut Bacteria “Perturbed” by Antibiotics
  • Shook Hardy & Bacon LLP
  • USA
  • March 17 2017

A study has purportedly suggested that antibiotic treatments for foulbrood and other pathogens can disrupt the gut microbiota of honeybees


FDA refuses to re-classify tooth-whitening products as drugs
  • Shook Hardy & Bacon LLP
  • USA
  • May 2 2014

The U.S. Food and Drug Administration (FDA) has denied a Citizen Petition asking the agency to re-categorize tooth-whitening products as drugs


Lessons Learned From the Intuitive Surgical Lawsuits: The Benefits of Partnering With Independent Educational Firms
  • Shook Hardy & Bacon LLP
  • USA
  • January 30 2017

Though a number of companies manufacture and sell surgical robots in the United States, Intuitive Surgical has been the primary target of product


Seventh Circuit Dismisses Eye Drop Case for Lack of Injury
  • Shook Hardy & Bacon LLP
  • USA
  • March 27 2017

The U.S. Court of Appeals for the Seventh Circuit has decertified and dismissed with prejudice a class action alleging the packaging of prescription


NJ court affirms role of learned intermediary doctrine
  • Shook Hardy & Bacon LLP
  • USA
  • May 26 2015

A New Jersey court overseeing the centralized litigation regarding the human tissue product AlloDerm has issued a noteworthy ruling in a bellwether


FDA issues warning to star scientific for antabloc and CigRx products
  • Shook Hardy & Bacon LLP
  • USA
  • January 9 2014

The U.S. Food and Drug Administration (FDA) has warned former Star Scientific, Inc. CEO Jonnie Williams that the company makes therapeutic claims for


FDA steps up issuance of warning letters to cosmetic and dietary supplement companies
  • Shook Hardy & Bacon LLP
  • USA
  • April 1 2015

The Food and Drug Administration (FDA) has issued a number of Warning Letters to cosmetic and dietary supplement companies over the last several


DMAA cleared as cause of soldiers’ deaths
  • Shook Hardy & Bacon LLP
  • USA
  • August 15 2013

A safety review panel formed by the U.S. Army and Department of Defense (DOD) has issued a report which concludes that although DMAA (1


Landmark Texas Supreme Court decision: learned intermediary doctrine applies in prescription drug cases, no DTC exception
  • Shook Hardy & Bacon LLP
  • USA
  • June 12 2012

Addressing the issue squarely for the first time, the Texas Supreme Court has unanimously adopted the learned intermediary doctrine in the prescription drug context thereby confirming that manufacturers are only obligated to warn doctors of the risks of prescription medicines